Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Gains from Sales and Divestitures (2018 - 2025)

Nephros (NEPH) has 8 years of Gains from Sales and Divestitures data on record, last reported at $160843.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures changed N/A year-over-year to $160843.0; the TTM value through Sep 2025 reached $160843.0, changed N/A, while the annual FY2024 figure was $42167.0, 77.51% down from the prior year.
  • Gains from Sales and Divestitures reached $160843.0 in Q3 2025 per NEPH's latest filing, up from $146114.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $187503.0 in Q4 2023 and bottomed at $23781.0 in Q4 2021.
  • Average Gains from Sales and Divestitures over 5 years is $94871.6, with a median of $58961.0 recorded in 2025.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 99.96% in 2021, then skyrocketed 319.17% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $23781.0 in 2021, then skyrocketed by 88.1% to $44732.0 in 2022, then surged by 319.17% to $187503.0 in 2023, then crashed by 77.51% to $42167.0 in 2024, then skyrocketed by 281.44% to $160843.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $160843.0 in Q3 2025, $146114.0 in Q2 2025, and $58961.0 in Q1 2025.